Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors

Journal of Clinical Oncology

Volumn 12, Issue 11, 1994, Pages 2277-2283

  Motzer, Robert J ^a   Bajorin, Dean F ^a   Schwartz, Lawrence H ^a   Hutter, Heidi S ^a   Bosl, George J ^a   Scher, Howard I ^a   Lyn, Peter ^a   Fischer, Patricia ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LACTATE DEHYDROGENASE; PACLITAXEL; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ALLERGIC REACTION; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0027996483     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.11.2277     Document Type: Article

References (44)

1. Rowinsky EK, Nave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent, J Natl Cancer Inst 82:1247-1259, 1990
2. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 22:665-667, 1979
3. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565, 1980
4. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
5. Thigpen T, Blessing J, Ball H, et al: Phase II trial of Taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 9:156, 1990 (abstr)
6. Holmes FA, Walters RS, Therlault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
7. Reichman BS, Seidman AD, Crown JP, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
8. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologie study. J Clin Oncol 9:1692-1703, 1991
9. Kohn E, Reed E, Link C, et al: A pilot study of Taxol, cisplatin, cyclophosphamide, and G-CSF in newly diagnosed stage III/IV ovarian cancer patients. Proc Am Soc Clin Oncol 12:257, 1993 (abstr 814)
10. Chou TC, Motzer RJ, Tong Y, et al: Computerized quantitation of synergy of various drugs against teratocarcinoma cells in vitro: A rational approach to clinical protocol design. Proc Am Assoc Cancer Res 35:254, 1994 (Abstr C-1520)
11. Bajorin DF, Sarosdy MF, Pfister DF, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
12. Williams S, Birch R, Einhorn LH, et al: Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
13. Motzer R, Geller N, Bajorin D, et al: Salvage chemotherapy for patients with germ cell tumors: The Memorial Sloan-Kettering Cancer experience (1979-1989). Cancer 67:1305-1310, 1991
14. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: Recent advances and future directions. J Natl Cancer Inst 84:1703-1709, 1992
15. Motzer RJ, Bajorin DF, Vlamis V, et al: Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 19:8-12, 1992 (suppl 12)
16. Einhorn LH, Weathers T, Loehrer P, et al: Second line chemotherapy with vinblastine, ifosfamide, and cisplatin after initial chemotherapy with cisplatin, VP-16 and bleomycin(PVB16B) in disseminated germ cell tumors (GCT): Long term follow-up. Proc Am Soc Clin Oncol 11:196, 1992 (abstr C-599)
17. Motzer RJ, Gulati SC, Tong WP, et al: Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 53:3655-3847, 1993
18. Nichols C, Tricot G, Williams S, et al: Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939, 1989
19. Broun ER, Nichols CR, Kneebone P, et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124-128, 1992
20. Murphy BA, Motzer RJ, Bosl GJ: Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors: The need for alternative strategies in the investigation of new agents in germ cell tumors. Invest New Drugs 10:327-330, 1992
21. Motzer RJ, Dmitrovsky E, Miller WH, et al: Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. Cancer 72:3313-3317, 1993
22. Gold EJ, Bosl GJ, Itri LM: Phase II trial of 13 cis-retinoic acid in patients with advanced nonseminomatous germ cell tumors. Cancer Treat Rep 68:1287-1288, 1984
23. Chun H, Bosl GJ: Phase II trial of mitoguazone in patients with refractory germ cell tumors. Cancer Treat Rep 69:461-462, 1985
24. Chun H, Bosl GJ, Golbey RB: Phase II trial of 1,2 diamino-cyclohexane-(4-carboxyphthalato) platinum (II) in patients with refractory germ cell tumors. Cancer Treat Rep 69:459-460, 1985
25. Motzer RJ, Bosl GJ, Tauer K, et al: Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Cancer Treat Rep 71:197-198, 1987
26. Ettinger DS: Evaluation of new drugs in untreated patients with small-cell lung cancer: Its time has come. J Clin Oncol 8:374-377, 1990
27. Evans WK, Eisenhauer EA, Cormier Y, et al: Phase II study of amonafide. Results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer. J Clin Oncol 8:390-395, 1990
28. Ettinger DS, Finkelstein DM, Abeloff MD, et al: Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: An Eastern Cooperative Oncology Group Randomized study. J Natl Cancer Inst 84:1077-1084, 1992
29. Hitchins RN, Holden L, Newlands ES, et al: Single agent etoposide in gestational trophoblastic tumors. Eur J Cancer Clin Oncol 24:1041-1046, 1988
30. Roth BJ, Dreicer R, Einhorn LH et al: Paclitaxel in previously untreated, advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 13:230, 1994 (abstr C-704)
31. Honvich A, A'Hearn R, Gildersleve J, et al: Prognostic factor analysis of conventional dose salvage therapy of patients with metastatic non seminomatous germ cell cancer. Proc Am Soc Clin Oncol 12:232, 1993 (abstr 715)
32. Droz JP, Kramar A, Nichols C, et al: Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: Assignment of prognostic groups. Proc Am Soc Clin Oncol 12:229, 1993 (abstr 704)
33. Broun ER, Nichols CR, Einhorn LH, et al: Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 68:1513-1515, 1991
34. Linkesch W, Greinix HT, Hocker P, et al: Longterm follow up of phase I/II trial of ultra-high carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc Am Soc Clin Oncol 12:232, 1993 (abstr 717)
35. Weiss RB, Donehower RC, Wiemik PH, et al: Hypersensitivity reactions from Taxol. J Clin Oncol 8:1263-1268, 1990
36. Rowinsky EK, McGuire WP, Guarnieri T, et al: Cardiac disturbances during the administration of taxol. J Clin Oncol 9:1704-1712, 1991
37. Arbuck SG, Canetta R, Onetto N, et al: Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 20:31-39, 1993
38. Bosl GJ, Gluckman R, Geller N, et al: VAB-6: An effective chemotherapy regimen for patients with germ cell tumors. J Clin Oncol 4:1493-1499, 1986
39. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
40. Ahmed T, Bosl G, Hajdu S: Teratoma with malignant transformation in germ cell tumors in men, Cancer 56:860-863, 1985
41. Williams SD, Einhorn LH, Greco A, et al: VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer 46:2154-2158, 1980
42. Wheeler BM, Loehrer PJ, Williams SD, et al: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28-34, 1986
43. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 4:1-15, 1993 (suppl 3)
44. O'Reilly SM, Rustin GJS, Smith DB, et al: Single agent activity of carboplatin in patients with previously untreated nonseminomatous germ cell tumors. Ann Oncol 3:163-164, 1992